Special clinical interests in gynaecological cancers (endometrial, ovarian, vulva, cervical) and colorectal cancers (bowel and rectum).
Dr Christos Mikropoulos trained at the South Thames rotation in Clinical Oncology and completed training in 2016.
He completed an MSc with Newcastle University in 2008 and an MD (Research) degree with University of London (ICR) in 2013. He worked at QEHB as a Consultant for a year in urogenital and gynaecological cancers. Currently he works at Maidstone (Kent Oncology Centre) and treats patients with urogenital, gynaecological and colorectal cancers. He also supports haematological patients with radiotherapy treatments.
- Lower gastrointestinal (GI) cancers
NHS Hospital / current post(s)
- Clinical Oncologist, Kent Oncology Centre
- Co-investigator and developer of the GENPROS study, which is a non-interventional study that will collect clinical outcome data for men diagnosed with prostate cancer with a known germline genetic predisposition.
- Co-investigator and developer of the GENPET study, which is an imaging single arm study assessing the sensitivity of F-Choline-PET to detect nodal metastases in men with a germline BRCA mutation.
- Co-investigator and developer of the BARCODE-1 study – a prostate cancer screening study which will genetically profile 5000 men and identify the top 10% men at most genetic risk and offer them a diagnostic prostatic biopsy.
- Member of the Royal College of Physicians (MRCP)
- Fellow of the Royal College of Radiologists (FRCP)
- Member of the European Society of Medical Oncology (ESMO)
- Member of the European Society of Therapeutic Radiation Oncology (ESTRO)
- Merit Award GU ASCO 2014 for Poster Presentation on ‘PROFILE: Results of a pilot study on targeted prostate cancer screen for men with family history of prostate cancer’.
- 2014 Ross RCR Poster Award for ‘The prevalence of the HOXB13 mutation in UK men and correlation with phenotype and outcomes’.
- Merit Award GU ASCO 2015 for the Poster Presentation on ‘The IMPACT study: Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in men at higher genetic risk and controls: Prostate-Specific Antigen Velocity as a predictive biomarker in a prospective Prostate Cancer Screening Study of Men with genetic predisposition.’